Profil
François Thomas is currently a Director at Eyevensys SAS, Axilum Robotics SAS, GamaMabs Pharma SA, Inotrem SA, Biomodex SAS, Cardiawave SA, IntegraGen SA, Aelis Farma SA, Quadrille Capital SAS, and Thomas Conseil.
He previously held positions as Chairman & Chief Executive Officer at Cytheris SA, Chairman at INSERM Transfert Initiative SAS, Independent Director at YM BioSciences, Inc., Director at Novexel SA, Director at CropDesign NV, Managing Director & General Manager at Bioserve Ltd., Director at Sensorion SA, Non-Executive Director at BerGenBio ASA, Director-Licensing & Medical Affairs at Serono Genetics Institute SA, Vice President-Clinical Development at Ipsen SA, Managing Partner at INSERM Transfert SA, Venture Partner at Sofimac Régions SAS, Venture Partner at Atlas Venture SARL, Assistant Professor at Institut Gustave Roussy EURL, Member-Supervisory Board at Step Pharma SAS, and Head-Corporate Finance at Bryan Garnier Securities SAS. Dr. Thomas holds an MBA from the Massachusetts Institute of Technology and a graduate degree from Universite Paris Cite.
Postes actifs de François Thomas
| Sociétés | Poste | Début |
|---|---|---|
| AELIS FARMA | Directeur/Membre du Conseil | 01/01/2022 |
| INTEGRAGEN | Directeur/Membre du Conseil | 14/06/2018 |
Quadrille Capital SAS
Quadrille Capital SAS Investment ManagersFinance Quadrille Capital invests in middle-market companies located in Europe and United States. The firm targets companies operating in the fields of software technology, internet services, consumer and healthcare sectors. It provides financing for buyout and growth stage capital transactions. | Private Equity Investor | 01/10/2021 |
Axilum Robotics SAS
Axilum Robotics SAS Miscellaneous Commercial ServicesCommercial Services Develops and commercializes robotic solutions designed to assist medical professionals in the implementation of technical gestures | Directeur/Membre du Conseil | - |
Thomas Conseil | Corporate Officer/Principal | 01/01/2005 |
Biomodex SAS
Biomodex SAS Commercial Printing/FormsCommercial Services Operates as a medical technology company that provides 3D printing solutions | Directeur/Membre du Conseil | - |
Eyevensys SAS
Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Develops non-viral gene therapy process for the treatment of ocular illnesses | Directeur/Membre du Conseil | - |
Cardiawave SA
Cardiawave SA Medical SpecialtiesHealth Technology Develops a non-invasive medical device to treat a heart condition called aortic stenosis | Directeur/Membre du Conseil | - |
Inotrem SA
Inotrem SA BiotechnologyHealth Technology Operates as a clinical stage biotechnology company that develops immunotherapies | Directeur/Membre du Conseil | - |
| ░░░░░░░░ ░░░░░░ ░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
Anciens postes connus de François Thomas
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░░░ ░░░░░░░░ ░░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░░ ░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
Formation de François Thomas
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 28 |
|---|---|
Serono Genetics Institute SA
Serono Genetics Institute SA Miscellaneous Commercial ServicesCommercial Services Operates a biotechnology company specializing in synthetic DNA and genetic analysis | Commercial Services |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Produces cancer-related drug products | Health Technology |
Ipsen SA
Ipsen SA Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
IntegraGen SA
IntegraGen SA Medical/Nursing ServicesHealth Services Develops cutting edge genome analysis products | Health Services |
Massachusetts Institute of Technology
Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
Novexel SA
Novexel SA Pharmaceuticals: MajorHealth Technology Researches and develops anti-infective drugs for the treatment of bacterial and fungal infections | Health Technology |
Cytheris SA
Cytheris SA Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs for immune modulation | Health Technology |
CropDesign NV
CropDesign NV Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company that develops traits for cereal crops | Commercial Services |
INSERM Transfert SA
INSERM Transfert SA Investment ManagersFinance ITSA is an active private equity investment manager focused exclusively on the French biomedical sector, particularly on areas related to INSERM's medical research effort. They favor projects in fields including therapeutic agents, medical devices, diagnostics, tools and technological platforms. The firm invests between EUR 100 and 300 thousand in pre-seed and seed financing. ITSA's investment criteria include sound science, a driven management team, strong IP, a realistic business model with a clearly defined market, and a competitive milestone-driven schedule. They seek to invest in ambitious projects addressing unmet medical needs and potentially leading to dominant market positions. The firm may act as a co-founder, generally sits on the board of their portfolio companies and actively participates in their strategic decisions. | Finance |
Sofimac Régions SAS
Sofimac Régions SAS Investment ManagersFinance Sofimac Régions is an active manager which specializes in making equity investments in unlisted small businesses mainly based in the Auvergne, Rhône-Alpes, Limousin, and Provence-Alpes-Côte d'Azur regions in France. The firm invests in businesses in the technology and industrial sectors at all stages of development, from seed capital to buyouts. Sofimac Régions seeks to identify companies with good growth and valuation potential and carries out campaigns to identify potential investee companies. The firm analyzes potential investee company management, products, markets and strategy, as well as their historical and forecast financial statements and financing needs. The firm monitors investments through regular contacts with company management, assisting them with their strategic thinking. Their exit may be the sale of the company, a secondary buyout or an IPO. Sofimac Régions seeks to set up new innovative, high technology companies based on scientific, technological and marketing criteria as well as the founder's ability to successfully implement his corporate plan. The firm may co-invest alongside other seed or early-stage venture capital funds, investing within a framework of organizations that support innovation. They fund the costs of building a prototype and invest additional funds to mass produce and market the product if successful at the end of the seed stage. They evaluate start-up and early-stage projects in terms of technology, intellectual property rights, products and markets, choosing business plans based on the company's management capabilities and the potential to market their technology and products internationally. Sofimac Régions participates in investee company development through organic growth, acquisitions and ownership transfers in the manufacturing and services sectors, investing in companies with high growth potential. The firm coordinates financial engineering and maintains close relations with the investee company's management, providing financing over the medium-term with the aim of exiting after five to seven years. | Finance |
Atlas Venture SARL
Atlas Venture SARL Investment ManagersFinance Acts as an alternative investment manager | Finance |
INSERM Transfert Initiative SAS
INSERM Transfert Initiative SAS Investment ManagersFinance Acts as Venture Capital Fund | Finance |
Bioserve Ltd. | |
Sensorion SA
Sensorion SA Pharmaceuticals: MajorHealth Technology Operates as a research and development company that discovers drugs to treat inner ear disorders | Health Technology |
BerGenBio ASA
BerGenBio ASA Pharmaceuticals: MajorHealth Technology Develops drugs for aggressive, drug resistant cancers | Health Technology |
Institut Gustave Roussy EURL
Institut Gustave Roussy EURL Miscellaneous Commercial ServicesCommercial Services Provides cancer research services | Commercial Services |
Eyevensys SAS
Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Develops non-viral gene therapy process for the treatment of ocular illnesses | Commercial Services |
Axilum Robotics SAS
Axilum Robotics SAS Miscellaneous Commercial ServicesCommercial Services Develops and commercializes robotic solutions designed to assist medical professionals in the implementation of technical gestures | Commercial Services |
GamaMabs Pharma SA
GamaMabs Pharma SA Medical/Nursing ServicesHealth Services Specializes in developing monoclonal antibodies | Health Services |
Inotrem SA
Inotrem SA BiotechnologyHealth Technology Operates as a clinical stage biotechnology company that develops immunotherapies | Health Technology |
Aelis Farma SA
Aelis Farma SA BiotechnologyHealth Technology Operates as a biotechnology company which develops drugs for brain diseases | Health Technology |
Quadrille Capital SAS
Quadrille Capital SAS Investment ManagersFinance Quadrille Capital invests in middle-market companies located in Europe and United States. The firm targets companies operating in the fields of software technology, internet services, consumer and healthcare sectors. It provides financing for buyout and growth stage capital transactions. | Finance |
Biomodex SAS
Biomodex SAS Commercial Printing/FormsCommercial Services Operates as a medical technology company that provides 3D printing solutions | Commercial Services |
Cardiawave SA
Cardiawave SA Medical SpecialtiesHealth Technology Develops a non-invasive medical device to treat a heart condition called aortic stenosis | Health Technology |
Step Pharma SAS
Step Pharma SAS Pharmaceuticals: MajorHealth Technology Develops drugs for immunosuppressive therapies | Health Technology |
Thomas Conseil | |
Bryan Garnier Securities SAS
Bryan Garnier Securities SAS Financial ConglomeratesFinance Functions as an investment fund | Finance |
Universite Paris Cite
Universite Paris Cite Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
















